Based: Santa Monica, CA
Investors: Alta Partners, Bear Stearns Health Innoventures, Fukui JAFCO Company, HBM BioVentures, Lombard Odier Darier Hentsch, Nextech Venture, OrbiMed Advisors, Undisclosed Investor, Undisclosed Venture Firm
Scoop: Agensys is developing fully-human monoclonal antibodies (MAbs) to treat solid tumor cancers. The funding is being used to advance the company's prostate cancer program through Phase II and bring three more products into clinical development by the end of 2008. In November 2007, Japan's Astellas bought Agensys for $387 million plus up to $150 million more in milestones. Antibodies will likely play an ever-growing role in cancer treatments, and are expected to command a $32 billion market by 2015.